What are fibroblast growth factor receptor 3 (FGFR3) autoantibodies, how are they tested, and which diseases are associated with positive FGFR3 autoantibodies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FGFR3 Autoantibodies: Definition, Testing, and Associated Diseases

FGFR3 (fibroblast growth factor receptor 3) autoantibodies are pathogenic antibodies that target the intracellular domain of FGFR3 protein on sensory neurons in dorsal root ganglia, and they identify a specific subgroup of patients with sensory neuropathy, particularly sensory neuronopathy (SNN) and small fiber neuropathy (SFN). 1, 2

What Are FGFR3 Autoantibodies?

FGFR3 autoantibodies are antibodies directed against fibroblast growth factor receptor 3, a protein expressed on sensory neurons. These antibodies:

  • Bind directly to sensory neurons within dorsal root ganglia (DRG) 1
  • Are pathogenic, not merely biomarkers—they directly cause neuronal hyperexcitability and mechanical hypersensitivity by acting on DRG neurons 1
  • Target specific epitopes in two main domains:
    • Juxtamembrane domain (JMD)
    • Tyrosine kinase domain (TKD), with TKD-targeting antibodies associated with more severe clinical impairment 3
  • The identified epitopes cover functionally relevant sites of the FGFR3 protein, and some react in a phosphorylation-state dependent manner 3

How Are They Tested?

Testing should be performed using ELISA as the primary method, with immunofluorescence staining on rat dorsal root ganglion (DRG) sections as confirmatory testing for samples near the cut-off threshold. 4

Primary Testing Method:

  • ELISA using the intracellular domain of FGFR3 as the target antigen 4, 2
  • Normal titer: <3,000; positive range: 3,100-30,000 (mean ~10,688) 5
  • Critical caveat: Cut-off values are laboratory-specific, and optical density values can vary significantly between laboratories 4
  • Samples with optical densities near the cut-off should be interpreted cautiously 4

Confirmatory Testing:

  • Double immunofluorescence staining on rat DRG sections 4
    • 68.8% of ELISA-double-positive sera stain small DRG neurons, colocalizing with commercial anti-FGFR3 antibody
    • Only 5% of ELISA-negative sera show positive DRG binding
    • DRG-positive samples show significantly higher ELISA optical densities 4
  • Cell-based assay using cells transfected with FGFR3 can confirm serum reactivity 2

Initial Screening (Historical):

  • Protein array screening was used in discovery phase but is not standard clinical practice 2

Important testing note: Inter-laboratory concordance is substantial (81%, Cohen's kappa = 0.61), but discordance occurs near cut-off values, emphasizing the need for confirmatory DRG staining when results are borderline 4

Diseases Associated with Positive FGFR3 Autoantibodies

FGFR3 autoantibodies define a specific clinical phenotype characterized by non-length-dependent sensory neuropathy with dorsal root ganglia dysfunction. 2

Primary Associated Conditions:

1. Sensory Neuronopathy (SNN) - Most Common

  • 82% of anti-FGFR3 positive patients fulfill criteria for probable SNN 2
  • Non-length dependent pattern in 87% of cases (distinguishing feature) 2
  • Presents with distal lower-extremity paresthesia (66%), unsteady gait (26%), foot drop (11%) 5

2. Small Fiber Neuropathy (SFN)

  • Distinct clinical phenotype with small-fiber involvement 1
  • Associated with neuropathic pain as a consistent feature 1
  • Antibodies cause sensory neuron hyperexcitability leading to mechanical hypersensitivity 1

3. Sensorimotor Neuropathy

  • Mixed axonal and demyelinating features on EMG in some cases 5
  • Distal lower-extremity weakness (mild to severe) 5
  • Demyelination found in 5/6 nerve biopsies 5

Clinical Context:

Autoimmune/Dysimmune Context (most common):

  • Found in 11/38 (29%) patients with SN in autoimmune context 2
  • Associated systemic autoimmune diseases in 6/27 patients 5
  • One control patient with lupus had anti-FGFR3 antibodies (without recorded neuropathy) 2

Idiopathic Cases:

  • Found in 5/46 (11%) patients with idiopathic sensory neuropathy 2

Paraneoplastic Association:

  • 7/27 patients had history of cancer 5
  • One case report describes association with Hodgkin lymphoma in remission 6

Distinctive Clinical Features:

  • Trigeminal nerve involvement is frequent 2, 6
  • Pain is a prominent feature 2
  • Adie pupil reported in at least one case 6
  • Decreased distal sensation to pinprick (59%) and loss of vibration sensation (37%) 5
  • Symptom onset can be acute (15% of cases) 5

Diagnostic Performance:

  • Sensitivity: 19% for idiopathic or dysimmune SN
  • Specificity: 99.6%
  • Positive predictive value: 94.1%
  • Negative predictive value: 77.3% 2

The high specificity and positive predictive value make anti-FGFR3 antibodies a valuable diagnostic marker when positive, though the low sensitivity means their absence does not exclude sensory neuropathy.

Treatment Response

Intravenous immunoglobulin (IVIg) shows therapeutic benefit in the majority of treated patients (8/10 patients responded) 5, with significant improvement even when treatment is delayed 6. This supports the autoimmune pathogenesis and positions both FGFR3 antibodies and FGFR3 signaling as actionable therapeutic targets 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.